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ZincGPR39 is a class A G protein-coupled receptor involved in zinc binding and glucose homeostasis regulation,
among other physiological processes. GPR39 was originally thought to be the receptor for obestatin peptide
but this view has been challenged. However, activation of this receptor by zinc has been clearly established.
Recent studies suggest that low GPR39 expression, due to deﬁcient zinc levels, is involved in major depressive
disorder.Wehave previously reported that zinc can alter receptor–receptor interactions and favor speciﬁc recep-
tor interactions. In order to unravel the effect of zinc on speciﬁc G protein-coupled receptor association processes,
we have performed FRET and co-immunopuriﬁcation studies with GPR39 and 5-HT1A and GalR1 which have
been shown to dimerize. Our results suggest that zinc can modulate the formation of speciﬁc 5-HT1A-GPR39
and GalR1-5-HT1A-GPR39 heteroreceptor complexes under our experimental conditions.
Wehave analyzed the differences in signaling between themono-homomeric receptors 5-HT1A, GalR1 andGPR39
and the heteroreceptor complexes between them Our results show that the GPR39-5-HT1A heterocomplex has
additive functionalities when compared to the monomeric–homomeric receptors upon receptor activation. In
addition, the heterocomplex including also GalR1 shows a different behavior, upon exposure to the same
agonists. Furthermore, these processes appear to be regulated by zinc. These ﬁndings provide a rationale for
the antidepressive effect widely described for zinc because pro-depressive heterocomplexes are predominant
at low zinc concentration levels.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
GPR39 is a member of the rhodopsin family of class A G protein-
coupled receptors (GPCRs) [1]. It was ﬁrst cloned in 1997 [2] and
described as two isoforms; the full-length receptor (GPR39-1a) and a
truncated transmembrane domain isoform (termed GPR39-1b). Until
now, however, its speciﬁc ligand is still a matter of debate. For instance,
it was initially thought to be the receptor for the obestatin peptide [3],
but no clear reproducible data have been reported to conﬁrm this pro-
posal [4,5]. Furthermore, activation of the receptor by zinc, which
would function as an agonist only for the full-length GPR39-1a isoform
[6], has been also widely described [4,5].
A wide variety of physiological roles have been described for this
receptor, like regulation of gastrointestinal and metabolic functions [7]
and apoptosis protection [8], or its involvement in certain disorders
like obesity type 2 associated diabetes mellitus [9], pancreatic islet
dysfunction [10], cancer [11] and depression [12,13]. In this work wecular, Departament d'Enginyeria
ant Nebridi 22, 08222 Terrassa,have focused on the potential involvement of GPR39 in depression.
There is consensus on the fact that GPR39 can be activated by zinc and
there is growing evidence that this interaction may be involved in
the pathophysiology of depression [12,13]. One of the main current hy-
potheses is that a zinc deﬁcient environment can result in decreased
expression of GPR39 and this may be linked to depressive behavior.
The association of GPR39, zinc and depression is appealing and may be
parallel to our observed effect of zinc on5-hydroxytriptamine 1A receptor
(5-HT1A)-galanin receptor 1 (GalR1) heteromer [14]. The current study
was based on a previous hypothesis, which suggested that 5-HT1A-GalR1
heteromer is involved in major depressive disorder [15], and it was
concluded that zinc may disrupt the 5-HT1A-GalR1 heteromer through
its speciﬁc interaction with 5-HT1A and therefore could favor a healthy
phenotype [14]. These data could help explain the beneﬁts of zinc supple-
mentation (used in depression treatment) that have been widely recog-
nized [16,17]. Thus, the main scheme of this working hypothesis is
based on the complex interplay among the GPCR-zinc-depression triad.
It is plausible that the three aforementioned receptors, GPR39, 5-HT1A
and GalR1, can be interlinked and play a complementary role in the
molecular mechanism of depression. This is supported by the concept
that GPCRs can form homo and heteroreceptor complexes, which may
act as new signaling units [18–20]. 5-HT1A forms heteroreceptor
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pears valid that 5-HT1A, GPR39 and GalR1 can arrange into different olig-
omerization states where 5-HT1A is the hub receptor.
We have experimentally tested the existence of the proposed inter-
actions in order to gain new insights into this question. First, we have
analyzed the potential 5-HT1A-GPR39 interactions, because 5-HT1A-
GalR1 heteromers hadbeen already described [14,15].Wehave validated
that there is co-localization between the two receptors bymeans of ﬂuo-
rescence microscopy. By using a complementary approach combining
FRET (Förster resonance energy transfer) and co-immunopuriﬁcation,
we validate the interaction of 5-HT1A with GPR39 and GalR1 together
or separately. Finally, we have used a gene reporter assay to unravel
the possible signaling differences between mono-homomeric receptors
and heteroreceptor complexes in their corresponding signal transduc-
tion pathways. We have analyzed 5-HT1A-GPR39 and 5-HT1A-GPR39-
GalR1 heteroreceptor complexes activities by measuring its capacity to
induce the transduction over the serum response element (SRE) andnu-
clear factor κβ response element (NFκβ-RE). Our results show that
GPR39-5-HT1A heterocomplex has additive functionalities when com-
pared to the monomeric–homomeric receptors upon their activation.
In addition, the complex including also GalR1 shows a different behavior
upon exposure to the same agonists. These results could reﬂect that both
oligomerization forms could be present at the cell membrane and that
the presence of one or another would depend on a speciﬁc regulation
mechanism that may be modulated by zinc.
2. Materials and methods
2.1. Plasmid constructs
Rho-1D4 tag is an amino acid sequence corresponding to an epitope
located in the C-terminal tail of the bovine visual GPCR rhodopsinwhich
is speciﬁcally recognized by themonoclonal Rho-1D4 antibody. This tag
was added by inverse PCR to the expression vectors pCDNA3.1 contain-
ing either GalR1, or 5-HT1A or GPR39 genes (Missouri S&T cDNA
Resource Center, USA). pGPR39-EYFP and phrGFP2-5HT1A were obtained
by subcloningGPR39 into pEYFP-N3 and hrGFP2 into pCDNA3.1–5-HT1A
vectors respectively. Cloning was performed using in-fusion® HD
Cloning Kit (Clontech, France) according to themanufacturer's protocol.
p5-HT1A-ECFP and pGalR1-EYFP constructs were obtained as described
previously [15]. The pECFP-EYFP construct was obtained by subcloning
PCR-ampliﬁed EYFP into the pECFP empty vector using traditional
cloning. The used primers are listed below:
pCDNA3.1-GalR1-1D4:
Fw: 5ʹACGGAGACGAGCCAGGTGGCCCCGGCCTGACTCGAGTCTAGA
GGGCC 3ʹ.
Rv: 5ʹGGCCGGGGCCACCTGGCTCGTCTCCGTCACATGAGTACAATT
GGTTG 3ʹ
pCDNA3.1-5-HT1A-1D4:
Fw: 5ʹACGGAGACGAGCCAGGTGGCCCCGGCCTGACTCGATAGAG
GGCCCG 3ʹ.
Rv: 5ʹ GGCCGGGGCCACCTGGCTCGTCTCCGTCTGGCGGCAGAACTT
ACACT 3ʹ.
phrGFP2-5HT1A.
Fw: 5ʹ ACCGAGCTCGGATCCATGGTGAGCAAGCAGATCCTG 3ʹ.
Rv: 5ʹ ATCCATGGTGGATCCCACCCACTCGTGCAGGCTGCC 3ʹ.
pGPR39-EYFP.
Fw: 5ʹ CTCGAGCTCAAGCTTATGGCTTCACCCAGCCTCCC 3ʹ.
Rv: 5ʹ GCGACCGGTGGATCCGCAACTTCATGCTCCTGAAAACC 3ʹ.
The resulting constructs were sequenced to check both appropriate
cloning and unspeciﬁc mutation absence (Stabvida, Portugal).
2.2. Immunoﬂuorescence microscopy
HEK-293S GnTi− cells (EACC, UK)were seeded onto glass coverslips
for 24 h and transfected with pGPR39-EYFP together with p5HT1A-1D4using polyethylenimine (PEI) (Polysciences, Germany). 24 h after trans-
fection, cells were washed with phosphate buffer saline (PBS) (Sigma-
Aldrich, Spain) and ﬁxed with formalin 3.7% (Sigma-Aldrich, Spain)
for 20 min. After washing twice with PBS, cells were permeabilized
and blockedwith blocking buffer (5% skimmedmilk in Tris buffer saline
(TBS) during 1 h at room temperature (RT). Then, cells were incubated
ﬁrst with the primary antibody, Rho-1D4 (dilution 1/2000 from stock)
for 30 min at RT. Then, after three washes with TBS buffer containing
0.1% tween-20 (Sigma-Aldrich, Spain), the samples were incubated
with anti-EYFP (dilution 1/200 from stock) (MBL, USA) overnight. Sub-
sequently, secondary antibody incubation was performed for 1 h with
anti-mouse-FITC (Sigma-Aldrich, Spain), three washing steps as de-
scribed before and 1 h more with anti-rabbit-Alexa Fluor® 555 (Life
technologies, USA). Finally, coverslips were mounted using Vectashield
mounting medium with DAPI (Vector Labs, UK). Representative cell
images were taken by inverted ﬂuorescence microscopy using an Nikon
Eclipse Ti microscope (Isaza, Spain) with a 100× objective.
2.3. Co-immunopuriﬁcation
The constructs encoding 5-HT1A-1D4 and GPR39-EYFP were tran-
siently transfected into HEK-293S GnTi− cells using PEI for heterodimer
presence analysis, and the same pair together with GalR1 for trimer
analysis. Equivalent quantities of each construct were used in both
transfections. The HEK-293S GnTi− cell line was used because it pro-
vides homogeneous glycosylation and allows a better visualization of
the protein bands in electrophoretic gels. Cells were routinely grown
in DMEM-F12 media (Labclinics, Spain) supplemented with 10% fetal
bovine serum (FBS), 1% penicillin-streptomycin (10,000 u/ml) and 1%
L-glutamine (200mM) (Sigma-Aldrich, Spain) at 37 °C and5%CO2 atmo-
sphere. 48 h after transfection, cells were treated with 10 mM dimethyl
apimidate (Sigma-Aldrich, Spain), pH 8–9, in non-supplemented
DMEM-F12 media for 1 h at RT. Then cells were harvested and pelleted
at 4000 g during 20 min. The pellet was then solubilized in 10 ml per
harvested plate of MES buffer containing 2% Triton X-100 and 100 μM
of phenylmethylsulfonyl ﬂuoride at 4 °C during 1 h. Solubilized cells
were centrifuged, at 35,000 rpm, for 35 min at 4 °C and the supernatant
was incubated by gently nutating with CNBr-activated Sepharose 4B
Fast Flow (GE healthcare, Spain) coupled to the Rho-1D4 antibody
(Cell Essentials, US) during 2.5 h. The sepharose beads were recovered
andwashedwith 50mMMES buffer, pH 6.0 (Sigma-Aldrich, Spain) con-
taining 0.05% dodecyl maltoside (DM) (Anatrace, UK) for ﬁve times.
Elution was performed during 3 h with 50 mM MES buffer pH 6.0
containing 0.05%DMand 0.5mMRho-1D4 9-mer peptide (TETSQVAPA)
(Unitat de Tècniques Separatives i Síntesi de Pèptids, Universitat de
Barcelona, Spain).
2.4. Immunoblot analysis of heterocomplexes
Eluted samples were mixed with denaturing loading buffer and
subjected to SDS-PAGE (3–14%). The gel was run for 40 min at 250 V
in Laemmli running buffer and using SDS7B2 pre-stained marker
(Sigma-Aldrich, Spain) as a protein standard. The proteins were subse-
quently transferred onto a nitrocellulose membrane (Sigma-Aldrich,
Spain) and blocked with blocking buffer. The membrane was incubated
with the following pairs of antibodies, in three rounds separated by
antibody stripping using RestoreWestern blot Stripping Buffer (Thermo
Scientiﬁc, France). The ﬁrst immunoblotwas performed using anti-EYFP
antibody as primary antibody (1:100 dilution from stock) and anti-
rabbit-IgG-HRP as secondary antibody (1:5000 dilution from stock).
The second one was performed using anti-GalR1 as primary antibody
(1:100 dilution from stock) and anti-goat-IgG HRP (1:5000 dilution
from stock) as secondary antibody. The third immunoblot was per-
formed using Rho-1D4 (1:1000 dilution from stock) as primary anti-
body and anti-mouse-IgG-HRP as secondary antibody. All secondary
Fig. 1. 5-HT1A-GPR39 heterodimerization. (A–F) Co-localization of 5-HT1A and GPR39
expressed in HEK293S GnTi− cells. 5-HT1A corresponds to the green signal (A and D) and
GPR39 to red signal (B and E). Green and red signal overlap is shown by the yellowish
color giving the area of receptor co-localization (C and F). Pictures show the area of
colocalization (white arrows) of the two receptors, which in F is clearly demonstrated
along the cell membrane and endoplasmic reticulum. (G) FRET saturation curve between
5-HT1A and GPR39. N-FRET (normalized FRET values) are represented against the acceptor
to donor ratio. Speciﬁc FRET, corresponding to the co-transfection of hrGFP2-5-HT1A and
GPR39-EYFP, (●) is indicated from the saturation proﬁle of the curve. In contrast, unspeciﬁc
FRET (▲) measurements, corresponding to mixed populations of cells expressing single
receptors, exhibit a linear tendency corresponding to a non-speciﬁc interaction. Data
corresponds to the average of three independent experiments. Data reﬂect speciﬁc inter-
actions between the two receptors.
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nology, USA. Blots were developed using substrate WesternBright
ECL (Advansta, USA).
2.5. FRET experiments
2.5.1. 5-HT1A-GPR39 complex detection
HEK-293S GnTi− cells were transiently co-transfected with con-
structs corresponding to hrGFP2-5-HT1A acting as donor and GPR39-
EYFP acting as acceptor. hrGFP2-5-HT1A DNA amountwas kept constant
at 1 μg in all transfectionswhereas GPR39-EYFPwas gradually increased
as follows: 0 μg, 0.5 μg, 1 μg, 1.5 μg, 2 μg, 3 μg and 4 μg. 48 h after trans-
fection, cells were harvested and resuspended in PBS containing
0.1 g·l−1 CaCl2, 0.1 g·l−1MgCl2 and 0.1 g·l−1 D-glucose (Sigma-Aldrich,
Spain). Then, cells were seeded onto 96-well black plates. Cell concen-
tration was adjusted, by determining protein concentration with a
BCA kit (Sigma-Aldrich, Spain), to 1 mg/ml. Finally, FRET signals were
measured using an Inﬁnite M200 reader (Tecan, Switzerland). Fluores-
cence was measured at three different conditions: 1− Ex = 485 nm
and Em= 516 nm, for hrGFP2 signal detection; 2− Ex = 515 nm and
Em = 546 nm for EYFP signal detection; 3 − Ex = 485 nm and
Em = 546 nm for FRET signal detection. Mock transfected cells were
used for background subtraction. FRET between the two ﬂuorophores
was determined essentially as previously described [22].
2.5.2. GalR1-5-HT1A-GPR39 complex detection
To carry out this experimentwe used the following vectors: p5HT1A-
ECFP as donor, pGalR1-EYFP as acceptor and pECFP-EYFP as a negative
control. Cells were transfected in six well plates using the following
conditions: donor alone, donor and acceptor (1:1 ratio) and negative
control. Same transfections were repeated as described but also adding
pCDNA3.1-GPR39 at equivalent concentrations. FRET spectra were
recorded using an Inﬁnite M200 reader. Excitation wavelength was set
at 420 nm and emission wavelength range was set from 455 nm to
560 nm. Data was smoothed and normalized using Peakﬁt software
(Systat Software, USA).
2.6. Luciferase reporter gene assay
We used Bright-Glo™ Luciferase Assay System (Promega, Spain) to
detect receptor activation. Reporter gene vectors containing luciferase
transcriptionally driven by response elements (pGL4.33 and pGL4.32)
were used in these experiments. Cells were co-transfected, in each
case, with the corresponding reporter vector and receptors, at equiva-
lent DNA amounts, using 6 well plates. 24 h after transfection, cells
were transferred onto 96 well white plates (Perkin Elmer, USA) in
starving media (culture media without FBS). Cells were subsequently
treated during 4 h, after additional 24 h, with the appropriate ligand
concentration in Optimem (Life Technologies, USA). 8-OH-DPAT at a
concentration of 100 μM was used as 5-HT1A agonist, 100 μM ZnCl2 as
GPR39 agonist and 1 μM gal (1–29) as GalR1 agonist. Luciferase activity
was determined according to themanufacturer's protocolwith an Inﬁnity
M200 reader, using standard luminescence reading conditions. Experi-
ments were performed in triplicate, and four replicates were measured
in each experiment. Statistical analyses were performed by one tailed
paired t-test with GraphPad Prism (GraphPad Software Inc., USA). A
p value of 0.05 and lower was considered signiﬁcant.
3. Results
3.1. Immunoﬂuorescence microscopy
One of themain objectives of this work was to determine the poten-
tial formation of a 5-HT1A and GPR39 heteroreceptor complexes in cel-
lular model by means of FRET and co-immunopuriﬁcation assays. To
start with, ﬁrst we determined if the C-terminal tagged 5-HT1A-1D4and GPR39-EYFP receptors co-localized to the same cell compartment.
Double immunolabeling of the tagged 5-HT1A-1D4 receptor with
anti-1D4/FITC and the tagged GPR39-EYFP with the anti-EYFP/
Alexa-Fluor555 antibodies showed that both receptors share a similar
distributional pattern and signiﬁcantly co-localized in the membrane
cell surface and reticular compartments (Fig. 1A–F).3.2. Heterodimerization between 5-HT1A and GPR39 measured by FRET
We tested thepossible heteromer formation between both receptors
by means of the biophysical technique FRET spectroscopy. Using a
saturation assay we assessed speciﬁc FRET between the two receptors,
in cells co-expressing a constant amount of hrGFP2-5-HT1A (humanized
green ﬂuorescent protein 2 fused to the C-terminal tail of the 5-HT1A)
(donor) and an increasing concentration of GPR39-EYFP (GPR39
receptor fused to enhanced yellow ﬂuorescent protein) (acceptor). For
unspeciﬁc FRET measurements, two populations of cells were indepen-
dently transfected with a single construct and subsequently mixed. Our
data can be ﬁt to a hyperbolic curve with an asymptote tending to the
maximal FRET value (Fig. 1G), validating the speciﬁc interaction
between the two receptors. In contrast, unspeciﬁc FRET measurements
resulted in a linear relationship between n-FRET and acceptor-to-donor
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of cells expressing the individual receptors. Taken together, these
results demonstrate that there is speciﬁc complex formed between
GPR39 and 5-HT1A.3.3. 5-HT1A and GPR39 heteromer analysis using co-immunopuriﬁcation
We used co-immunopuriﬁcation in order to provide further support
to our FRET measurements on puriﬁed receptors. Heterocomplex
formation among the three receptors (including GalR1) was also tested
using the same methodology (Fig. 2A). For heterodimerization experi-
ments cells were co-transfected with equivalent amounts of 5-HT1A-1D4
and GPR39-EYFP. The same amount of GalR1 was added for hetero-
trimerization experiments. Immunopuriﬁcation was carried out by im-
munoafﬁnity chromatography using the Rho-1D4 monoclonal antibody.
GalR1-1D4 and 5-HT1A-1D4 were singly transfected, obtained separately
and immunopuriﬁed to be used as immunoblot controls. Immunoblot
analysis showed EYFP immunoreactive bands both in heterodimer and
heterotrimer lanes, but with a different migration pattern. Both lanes
showed two high molecular mass species as upper bands, but in the
case of the dimer two lower bands could be detected and only one in
the case of the trimer. No immunoreactive bands could be detected in
control lanes as expected. When the inmunoblot was carried out using
the anti-GalR1 antibody, immunoreactive bands appeared in the GalR1
control lane and in the trimer lane. Finallywhen the immunoblotwas per-
formed using Rho-1D4 antibody, we could detect signal in all lanes indi-
cating that the immunopuriﬁcation process worked successfully (Fig.
2A). These results indicated that we had puriﬁed the 5-HT1A-GPR39
heteromer and the GPR39-5-HT1A-GalR1 complex. It can be noted that
we could detect monomeric species for 5-HT1A and GalR1 corresponding
to the bands in the control lanes, but no further information could be de-
rived from the other bands in our denaturing conditions. It is also note-
worthy to indicate that in the trimer lane, the band intensity obtainedFig. 2. Speciﬁc heterooligomer formation between 5-HT1A-GPR39 and 5-HT1A-GPR39-GalR1. (A)
the 1D4 tag to 5-HT1A in combination with Rho-1D4 antibody coupled sepharose. Four lanes
GPR39-EYFP (c) and 5-HT1A-1D4 + GPR39-EYFP + GalR1 (d). Interaction between 5-HT1A-1D
and GalR1 is also detected. 5-HT1A-1D4 and GalR1-1D4 were used as control lanes. (B–C) FRET cur
two different conditions: 5-HT1A-ECFP + GalR1-EYFP (−) and 5-HT1A-ECFP + GalR1-EYFP + G
data are nudged 0.1 points to avoid overlap. No differences between both curves are seen, meaninfor GalR1 was lower than the intensity seen for the bands corresponding
to the other two proteins. In other to discard the possible predominance
of 5-HT1A-GPR39, when compared to 5-HT1A-GPR39-GalR1, we analyzed
the FRET curves between 5-HT1A-ECFP and GalR1-EYFP in the presence
and in the absence of GPR39 at equivalent amounts.
3.4. Heterotrimer conﬁrmation by FRET
In order to conﬁrm the existence of a putative complex formed
by our three working receptors, we measured FRET curves between
5-HT1A and GalR1 receptors in the presence and in the absence of
GPR39 and we compared them with those obtained using a negative
control, also in the presence and absence of the same receptor (Fig.
2B). FRET was apparent in both samples and it had exactly the same
shape. Two peaks could be clearly distinguished, one at 490 nm corre-
sponding to ECFP (enhanced cyan ﬂuorescent protein) and the other
at 527 nm corresponding to EYFP, indicating that FRET was actually
taking place. Thus, 5-HT1A maintained its capacity to interact with
GalR1 in the presence of GPR39. The same result was obtained for the
negative control as expected (Fig. 2C).
3.5. SRE and NFκβ-RE luciferase reporter assays
Luciferase reporter assays were carried out with the purpose of
analyzing differences in receptors signaling due to heteromer forma-
tion. Brieﬂy, these assays are based on the fact that different GPCRs
are able to activate different regulatory elements via interaction with
speciﬁc G proteins populations. Therefore, activation of the different re-
sponse elements can be an indirectmeasurement of receptor activation.
In this particular case we measured SRE and NFκβ-RE activation. These
twopathwayswere chosen because of the following reasons: on the one
side, GPR39 signals via Gq, Gα12/13 and Gαs after stimulation with zinc,
and the activation of these G proteins leads to different pathways thatCo-immunopuriﬁcation immunoblots. Heterocomplexeswere immunopuriﬁed by adding
were loaded with the following samples: 5-HT1A-1D4 (a), GalR1-1D4 (b), 5-HT1A-1D4 +
4 and GPR39-EYFP is detected. Moreover, interaction between 5-HT1A-1D4, GPR39-EYFP
ves between 5-HT1A-ECFP and GalR1-EYFP. (B) Curves were obtained by cotransfection using
PR39 (−−−) at equivalent concentrations. 5-HT1A-ECFP + GalR1-EYFP + GPR39 (−−−)
g that 5-HT1A-GPR39 is not the predominant form.
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above, among others [12,23]. On the other side, 5-HT1A couples exclu-
sively to Gi/G0 that just activates SRE when 8-OH-DPAT is used as ago-
nist [15]. This different behavior in receptor signaling is used to derive
information about speciﬁc signaling of our studied receptors. The ability
of our receptors to signal as mentioned and according to previously
published data was experimentally tested (data not shown).
Heteromer exposure to 8-OH-DPAT or ZnCl2 resulted in a signiﬁcant
SRE response compared to non-exposed samples (p b 0.05) (Fig. 3A)
meaning that in the complex formed both receptors are active. Also,
exposure to both compounds at the same time gave a signiﬁcantly
higher response compared to those exhibited by each one of the com-
pounds on its own. These ﬁndings provide experimental evidence for
additive signaling upon co-activation. But, if we take into account that
the presence of zinc decreases 5-HT1A signaling ability, as it has been
published [24] and we have experimentally tested (see Fig. S1), a plau-
sible interpretation is that co-activation of both receptors increasesFig. 3. SRE andNFκβ-RE luciferase reporter geneassay of signaling over the 5-HT1A-GPR39heter
non-exposed cells to cells transfected but not agonist- stimulated. (A) SRE assay response af
was measured. In the three cases we obtain signals signiﬁcantly stronger compared to that of th
stronger signal than the ones obtained for single receptors demonstrating additive signaling. (B)
of the complex is not observed, because 5-HT1A cannot act through NFκβ-RE. In contrast, activa
obtained with ZnCl2 activation alone. (A–B) The data represent the means ± SD of three inde
tailed paired t-test. Signiﬁcantly different group comparisons are represented with *** (P b
(C) Schematic representation of signaling pattern changes betweenmono-homomeric forms an
formation. Adapted from [30,23]. Diamonds stand for receptors speciﬁc ligands.GPR39 activity. In contrast, no activity could be detected after 8-OH-
DPAT exposure alone (Fig. 3B) when analyzing NFκβ-RE signaling.
This result is in agreement with the fact that 5-HT1A is not able to signal
via NFκβ-RE and 8-OH-DPAT is not able to activate the GPR39 receptor.
However, ZnCl2 provided a signiﬁcant signal increase because of GPR39
activation. Furthermore, upon co-activation of the two receptors the
signal was signiﬁcantly increased when compared to the signal corre-
sponding to ZnCl2 exposure alone. These results could mean that in
the oligomeric state, and after co-activation of the two receptors, activa-
tion of 5-HT1A enhances GPR39 activity, as it is also suggested by SRE
results, or alternatively changes 5-HT1A signaling possibilities.
Strikingly, the presence of GalR1 blocks 5-HT1A and GPR39 signaling
(Fig. 4). Thus, no SRE activation could be detected, in the presence of
GalR1, when cells were incubated with 8-OH-DPAT or ZnCl2, whereas
a signiﬁcantly enhanced response could be observed when the sample
was treatedwith gal (1–29) peptide (galanin full length peptide).More-
over, stimulation with all agonists together yielded the same responseoreceptor complex.Mock transfected cells correspond to cells transfectedwithoutDNAand
ter stimulation of co-transfected cells with 8-OH-DPAT, ZnCl2 or both at the same time
e control (non-exposed). Co-activation by agonists, at the same time, gives a signiﬁcantly
NFκβ-RE response under the same conditions as earlier. In this case, 8-OH-DPAT activation
tion mediated by both compounds exhibits a signal signiﬁcantly higher compared to that
pendent experiments performed in triplicate. Statistical analyses were performed by one
0.001), ** (P ≤ 0.01) and * (P ≤ 0.05) and non-signiﬁcantly different as ns (P N 0.05).
d dimeric forms. Signaling throughNFκβ-RE is reinforced due to 5-HT1A-GPR39 heteromer
Fig. 4. SRE luciferase reporter gene assay of signaling over the 5-HT1A-GPR39-GalR1 complex. Mock transfected cells correspond to cells transfectedwithout DNA and non-exposed cells to
transfected but not agonist-stimulated cells. (A) SRE assay response was measured after stimulation of co-transfected cells with 8-OH-DPAT, ZnCl2, gal (1–29) alone, or all combined. No
responsewas obtained after stimulationwith 8-OH-DPAT, or ZnCl2,whereas a response could be detected afterGalR1 stimulation.Moreover, combined agonist activation of all receptors at
the same time gives the same response as GalR1 stimulation alone. The results indicate that the GalR1 presence blocks SRE signaling of 5-HT1A and GPR39 protomers in GalR1-5-HT1A-
GPR39 heteroreceptor complex. (A–B) The data represent the means ± SD of three independent experiments performed in triplicate. Statistical analyses were performed by one tailed
paired t-test. Signiﬁcantly different group comparisons are represented with *** (P b 0.001), ** (P ≤ 0.01) and * (P ≤ 0.05) and non-signiﬁcantly different as ns (P N 0.05). (B) Schematic
representation of the ERK 1/2-SRE signaling mechanism, found only in the GalR1 protomer while this signaling pathway is blocked in the 5-HT1A and GPR39 protomers of this
heteroreceptor complex. Other unknown pathways may be in operation at these protomers, adapted from [30,23]. Diamonds stand for receptors speciﬁc ligands.
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only GalR1 is able to transduce signals trough the analyzed pathway.
4. Discussion
The relationship between 5-HT1A-GalR1 heteromer, depression
and zinc has been previously postulated [14]. The potential linkage
of GPR39 with zinc and its role in depression has also been proposed
[4,17,25]. Also, a link between zinc and serotonin has been described,
suggesting that serotonin levels can modulate GPR39 expression [26].
However, in spite of these potential associations, no experimental
results have been reported on a direct relationship among the four
studied elements (5-HT1A-GalR1, GPR39, zinc and depression). Our
ﬁrst characterization validated the co-localization of 5-HT1A and
GPR39 in co-transfected cells and this work was continued by testing
for heteromerization. In fact, heteromerization was demonstrated
between the two receptors by means of FRET spectroscopy. 5-HT1A
was found to interact with both GalR1 and GPR39 suggesting a possible
heteroreceptor complex formed by these three receptors. Such hetero-
trimer receptor complexes have previously been described for different
GPCRs belonging to the same family [27,28].
The hypothesis was tested by using co-immunopuriﬁcation. This
method also allowed validating our previous FRET results indicating
the existence of a 5-HT1A-GPR39 heteromer. Immunoblots sustained
the hypothesis of a heterotrimer built up of these three receptors. In
the lane where the putative GalR1-5-HT1A-GPR39 complex had been
loaded, signals were obtained when using the antibodies against
each of the three proteins. However, in the lane where putative
5-HT1A-GPR39 heteromers had been loaded, the signal was missing
when using the anti-GalR1 antibody. Also control lanes showed signals
according to the antibody used. Furthermore, the signal corresponding
to GalR1 in the trimer lanewasweaker compared to controls and signals
corresponding to the other two proteins (Fig. 2A). As transfection hadbeen done with equivalent concentrations of each cDNA, two explana-
tionsmay be given for this result. On one side we can have the predom-
inance of the 5-HT1A-GPR39 heteromer versus the heterotrimer, and on
the other side the possibility of an artifact, due to the high level of
puriﬁed sample processed, cannot be ruled out. Alternatively, it is also
possible that different receptor expression levels could be responsible
for the different band intensities observed. FRET curves were recorded
between 5-HT1A and GalR1 in the presence or in the absence of GPR39.
The presence of GPR39 did not modify FRET between the other two
receptors, ruling out the possible predominance of 5-HT1A-GPR39
heterodimer. If 5-HT1A-GPR39 had prevailed over the GalR1-5-HT1A-
GPR39 trimer, FRET may not have been observed. Two mechanisms
can account for this behavior: the three receptors together form a stable
complex or the predominance of one over the two different possible
oligomers depends on cell type or speciﬁc physiological states.
The paradigm accepted for GPCRs oligomerization is that these
receptors, as protomers, use this strategy in order to exponentially
multiply their signaling capabilities [18]. Therefore, the main signaling
characteristics of the heterodimer and the heterotrimer were further
investigated.
Different signaling patterns were obtained for the heterodimer and
the heterotrimer that were also different from the signaling pattern
already published for the 5-HT1A and GalR1 heteromer. The 5-HT1A-
GalR1 heteromer shows trans-inhibition. Thus, when both receptors
are ligand activated, the activity is exactly the same as that obtained
when only one of the receptors is activated, either GalR1 or 5-HT1A
[15]. However, in the case of the GPR39-5-HT1A-GalR1 heterotrimer,
GalR1 acts as an antagonist blocking SRE signaling of the other two
receptor protomers regardless of the fact that it is agonist activated or
not. 5-HT1A-GPR39 meanwhile shows additive increase in signaling
along the SRE and NFκβ-RE pathways when both receptor protomers
are agonist activated. This result is not consistent with monomer–
homomer activity if we take into account that 5-HT1A is not able to
Fig. 5. Putativemechanism for zinc regulation of the balance of heteroreceptor complexes
in which 5-HT1A protomers participate with GPR39 and/or GalR1 protomers. High zinc
concentrations counteract 5-HT1A-GalR1 heteromer formation which is replaced by the
formation of 5-HT1A-GPR39 heteromers. Instead, when zinc concentrations decrease, the
5-HT1A-GalR1 heteromer develops as the dominant form due to the decrease in GPR39
expression. In this process, the 5-HT1A-GPR39-GalR1 heteroreceptor complex participates
as an intermediate form between the two heterodimers.
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confers new signaling opportunities to 5-HT1A and GPR39.
Our previous results strongly suggested that zinc disrupts the
5-HT1A-GalR1 heteromer [29]. Moreover, it was described that GPR39
knock-out mice exhibit depression-like behavior [25] and that zinc
deﬁciency strongly decreased GPR39 expression, and gave depression-
like behavior in rodents [12,13]. As a conclusion, the following scenario
is introduced: zinc concentration regulates the oligomerization state
between the three receptors GalR1-5-HT1A-GPR39 and this may have
consequences in the regulation of the depressive behavior. At high
zinc levels, 5-HT1A would no longer be able to interact with GalR1, but
could do so with GPR39, which is expressed at appropriate levels. In
contrast, at zinc deﬁcient levels, the predominant form would be
5-HT1A-GalR1 (vs 5-HT1A-GPR39) since this heteroreceptor complex is
not disrupted, and GPR39 levels might be low. The heterotrimer com-
plex formed from the three receptors could be an intermediate between
the two heterodimer complex states (Fig. 5). It is really difﬁcult to asso-
ciate a deﬁned zinc concentration to each of the aforementioned states
because the zinc concentration in a speciﬁc cell environment has not
been clearly established. It depends on the cell type, and also on the
speciﬁc state of the cell, varying from nM to mM concentrations [24].
However, according to previous reports [14,24] 50 μMshould be consid-
ered a zinc concentration high enough to prevent depression.
Future work must strive to unravel the exact regulatory mechanism
that zinc exerts on the oligomerization states among these distinct
receptors (5-HT1A-GPR39, 5-HT1A-GalR1 and GalR1-5-HT1A-GPR39)
followed by validation of our results using human samples, and suitable
techniques like PLA (proximity ligation assay). A full understanding of
this process will increase the possibilities in the ﬁeld of drug discovery
and design in order to develop novel antidepressant drugs, involving
e.g. speciﬁc divalent ligands for the heteroreceptor targets.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2015.09.003.
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